Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient

被引：35

作者：

Ranganath, Veena K.

Furst, Daniel E.

机构：

[1] Univ Calif Los Angeles, Div Rheumatol, Dept Med, David Geffen Sch Med, Los Angeles, CA 90025 USA

[2] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2007年 / 33卷 / 01期

关键词：

D O I：

10.1016/j.rdc.2006.12.011

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

During the 10-year period since the last review was done by Gardner and Furst, studies have furthered the knowledge of the use of disease-modifying antirheumatic drugs (DMARDs) in the elderly rheumatoid arthritis (RA) patient. This article briefly reviews the clinical pharmacology of humans as they age, and details the effects of aging on the specific pharmacokinetics and responses to commonly used DMARDs. There has been some progress in understanding the elderly RA patient; however, data are insufficient to provide much confidence in DMARDs effects in the elderly.

引用

页码：197 / +

页数：22

共 20 条

[1]

Long term effectiveness of antimalarial drugs in rheumatic diseases [J].